IPA and RIBOPRO Collaborate to Advance mRNA-Driven Antibody Discovery in Immunotherapy
Thursday, February 27, 2025
ImmunoPrecise Antibodies Ltd. a global company specialising in AI-powered antibody discovery and development, has formed a strategic collaboration with RIBOPRO, a technology provider focused on mRNA and lipid nanoparticle (LNP) technologies. This partnership aims to enhance the discovery and development of therapeutic antibodies by combining RIBOPRO’s mRNA-based antigen expression expertise with IPA’s in silico and wet-lab antibody discovery capabilities.
The collaboration integrates RIBOPRO’s expertise in mRNA sequence optimisation and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and AI-driven discovery workflows. The objective is to accelerate the development of new therapeutics by improving antigen presentation and immune responses, which play a key role in antibody discovery.
Traditional immunisation-based discovery platforms often face difficulties in expressing complex antigens effectively. This partnership seeks to overcome such challenges by utilising RIBOPRO’s proprietary mRNA and LNP technologies, enabling precise and efficient antigen expression. As a result, the approach may lead to more effective immune responses and potentially expedite the development of novel antibody therapeutics.
IPA employs AI-driven analytics alongside specialised wet-lab techniques to design and refine antibodies with strong clinical relevance. The incorporation of mRNA immunisation into IPA’s workflow is expected to enhance the accuracy and efficiency of its antibody discovery process.
The collaboration strengthens both companies’ ability to address complex challenges in antibody development through innovative solutions, reinforcing their commitment to advancing immunotherapy research.
Source: businesswire.com
